The high-profile failure of a clinically risky $12B acquisition is triggering activism and questioning pharma's M&A strategy. This may push companies to overpay for de-risked, post-Phase III commercial assets rather than take on the clinical development risk of earlier-stage bets, despite the higher price tag.

Servier is building its neurology pillar via acquisition, mirroring its successful oncology strategy. However, unlike past deals for commercial assets, the $1.55B Edgewise acquisition for its neuro programs hinges on a pivotal trial readout. This signals a higher risk tolerance and a strategic shift from buying revenue to buying high-stakes pipeline potential.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

Pharma's renewed interest in neuroscience is not for early-stage discovery. They are underwriting late-stage, de-risked assets with human proof-of-concept, understood mechanisms, and biomarker data. This strategy allows them to buy optionality on validated programs while avoiding the high cost of early failures.

After a period where investors heavily rewarded development-stage companies ahead of clinical data, a few underwhelming readouts have created caution. There is now more hesitation on the buy-side about being adequately compensated for taking on risk for major binary events, signaling a potential shift in risk appetite.

The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.